The company provides implantable Collamer lens product family (ICLs) and laser-based procedures, such as LASIK to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. More than 4,000,000 ICLs have been sold to date and STAAR has over 900 employees and markets lenses in over 75 countries.
Cyborg Score Rationale
STAAR operates in a specialized, high-growth niche (refractive eye surgery) with strong product penetration and global distribution. However, the company faces recent corporate governance challenges and competitive pressures, with ongoing acquisition discussions affecting strategic clarity.
Top Insights
Global market leader with 4M+ cumulative ICL implants demonstrating strong clinical adoption and surgeon confidence
Significant shareholder activism with Broadwood Partners (27.5% stake) pushing for strategic alternatives including acquisition discussions
Diverse geographic footprint across 75+ countries with direct presence in major markets (US, Japan, Germany, UK, Canada)
Specialized portfolio focused exclusively on ophthalmic surgery creates competitive moat but limits diversification
Named Competitors
LASIK and Refractive Surgery — Alternative vision correction procedure competing with ICL implants
General Ophthalmology Devices — Global eye care competitor with broader product portfolio
Recent Developments
(February 2026) Chief Legal Officer transition plan announced
(January 2026) Ongoing acquisition discussions with Alcon amid shareholder activism by Broadwood Partners
(January 2026) Broadwood Partners (27.5% shareholder) filed proxy contest to remove board directors over strategic direction
Open the full interactive STAAR Surgical Company report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.